Resources

The widely prescribed metformin was alone among oral antidiabetic agents to show a significant effect on cardiovascular (CV) risk in a meta-analysis of 40 select controlled trials. It reduced CV mortality by 26% relative to any other antidiabetic agent or placebo, but there was no effect on all-cause mortality.

Dr. Sheri Colberg, Ph.D., FACSM, knows that exercise presents its own special set of problems for control. The challenge of adding exercise into the mix as one more variable to figure out can feel overwhelming at times, and may stop your patients from trying. She has some tips from her …

In recent years, there has been increasingly more research performed on the clinical implications of sleep disordered breathing on insulin resistance and glucose intolerance. Carly Hingson, Doctor of Pharmacy Candidate, Mercer University College of Pharmacy puts it all together in her special report: Sleep-Related Breathing Disorders and Diabetes

In a set of mouse experiments, scientists attempt to learn more about why sulfonylureas eventually fail in the treatment of patients with type 2 diabetes. They may be more likely to keep working if they are used in moderation and stopped for a period of time.

The association of DM2 with solid tumors, and particularly with HCC (hepatocellular carcinoma), has been long suspected and several studies have reported increased mortality rates for neoplastic diseases in patients with DM2.

The nation’s obesity epidemic is exacting a heavy toll: The rate of new diabetes cases nearly doubled in the United States in the past 10 years, according to the CDC from a report released last Thursday. Diabetes experts said the findings show there is no end in sight to the …

The risk of developing diabetes is cut in half among rheumatoid arthritis patients who use hydroxychloroquine for treatment, according to research findings reported this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco.

Investigators combing the genome in the hope of finding genetic variants responsible for triggering early-onset diabetes may be looking in the wrong place, new research at the Stanford University School of Medicine suggests.

Doctors subconsciously favor whites over blacks, U.S. researchers said on Tuesday in a finding that may explain widespread racial disparities in health care in the United States.

Sanofi-aventis announced last week, that the U.S. Food and Drug Administration (FDA) approved Apidra(R) (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes.